
    
      Because the combination of gemcitabine and docetaxel has shown impressive activity in soft
      tissue sarcoma, we hypothesize that the addition of an antiangiogenesis agent (bevacizumab)
      would enhance the anticancer activity, as shown in other tumor types.
    
  